This trial is evaluating whether Non-invasive hemodynamic measurements will improve 7 primary outcomes in patients with Pulmonary Embolism. Measurement will happen over the course of 12-24 hours.
This trial requires 40 total participants across 1 different treatment group
This trial involves a single treatment. Non-invasive Hemodynamic Measurements is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"There are approximately 60,000 pulmonary emboli per year in the Unites States. A high proportion have no symptomatology. Many people hospitalized for PE have pulmonary hypertension." - Anonymous Online Contributor
"Non-invasive hemodynamic measures are helpful in the diagnosis of PE but only in patients with normal heart function. Hemodynamic methods alone are insufficient for diagnosis of other forms of PE." - Anonymous Online Contributor
"Non-invasive and inexpensive hemodynamic monitoring using PACS seems to be a safe and promising tool to predict outcome of patients undergoing cardiopulmonary resuscitation, and a large-scale prospective study seems an option." - Anonymous Online Contributor
"This report highlights some potentially curative cases of pulmonary embolism, using different treatment strategies. Although this report is limited by single-center studies, and as such this cannot show a cure rate for pulmonary embolism, it highlights some specific cases with significant benefit from treatment." - Anonymous Online Contributor
"The majority of patients who present to the emergency department with a suspected diagnosis of pulmonary embolism do not have a contraindication to anticoagulation. A careful history and physical exam are the most useful tools, as well as simple tests that evaluate for the presence of pulmonary embolism or its severity. Physicians should also consider the risks and benefits of anticoagulation, because some patients may be appropriate candidates for anticoagulation and others may not. Appropriate patient education and discussion regarding risks and benefits of anticoagulation is of paramount importance." - Anonymous Online Contributor
"Those at risk of pulmonary embolism have higher B-type natriuretic peptide levels, a greater cardiac index, and larger right ventricular end-diastolic volumes than are seen in those without pulmonary arterial hypertension." - Anonymous Online Contributor
"Factors that increase the risk of developing PE include: BMI under 18.5 kg/m, smoking, previous VTE, recent respiratory infection, and high baseline D-dimer levels. The majority of PE results from an embolus that is either sub-segmental (30%) or massive (70%).\n" - Anonymous Online Contributor
"Pulmonary embolism is a medical emergency with rapid progression toward death if untreated. PTE is an uncommon cause of sudden death. The incidence is unknown though several estimates have been made. PTE also has multiple subtypes that are now well characterized and can be differentiated by chest CT." - Anonymous Online Contributor
"Most of the side effects of these monitoring devices are related to the arterial puncture site and/or the blood flow interruption or the presence of venous clotting. Monitoring in the right upper chamber of the heart has the greatest probability of being related to a serious side effect. In our study, patients having implanted a pressure device for a long time showed a lower occurrence of this complication. Other side effects were as common." - Anonymous Online Contributor
"An improved prognostic profile for in-hospital mortality and length of stay in patients receiving non-invasive hemodynamic measurements as part of the initial management of severe sepsis was noted in patients treated at high-volume hospitals as compared with patients treated at low-volume hospitals." - Anonymous Online Contributor
"Measurement of pulse wave velocity and non-invasive central artery pressure might provide a reasonable substitute for invasive hemodynamic measurements, particularly in treating the elderly. Data from a recent study may lead physicians to consider the use of these non-invasive hemodynamic measurements instead of invasive hemodynamic measurements as a first line approach to treating patients with acute PE." - Anonymous Online Contributor
"Physicians who are contemplating an individual patient clinical trial for PE should consider the potential risk of pneumonitis and pulmonary embolism. Clinicians should consider the risk-benefit profile of individual patient and clinician risk-benefit ratios. At the time of referral, physicians may wish to consider the possibility that individual patient clinical trials may be of benefit to select PE patients or the subset of patients with the potential to derive the greatest benefit." - Anonymous Online Contributor